Breast cancers with high levels of CACNA1H (Cav3.2) (2nd, 3rd, 4th quartile) showed a significant elevation in levels of ESR1 and PGR compared to breast cancers with significantly low levels of Cav3.2 (1st quartile) (Fig. 8b). This evidence concerns the gene ESR1 and breast cancer.